Español
We are coming to the end of this year and through this post we want to reflect on the impact of OLIGOFASTX in the field of RNA in Spain.
Beyond the individual responsibilities of each partner, we have worked in coordination with the aim of creating an industrial fabric at national level and to make this project known internationally.
It is a pleasure to see the progress made and to express our thanks to each member of the consortium. The presence and results we have achieved are the result of a joint effort, providing a solid starting point for 2024.
This year, Oligofastx reaffirms its commitment to social transformation by actively supporting the proposals of the Spanish Federation for Rare Diseases (FEDER). Aware of the significant impact that collaboration can have on the lives of those facing rare diseases, we are proud to contribute to FEDER’s initiatives aimed at bringing about positive change in the social landscape.
A global stage: the participation of OLIGOFASTX and its partners in cutting-edge congresses
During 2023 our partners have been present at national and international conferences, actively contributing to the advancement of research and innovation in the field of oligonucleotides.
In March, Vito Genna of Nostrum Biodiscovery attended the RNA Leaders conference in Basel, Switzerland.
In June, Miguel Moreno represented aptaTargets at the International Conference on Oligonucleotides and Peptides, presenting his work with aptamers within the OLIGOFASTX consortium.
In September, Arthex Biotech attended the US RNA Leaders in Boston to discuss the development of RNA-based therapeutics. Our partners were also present at BioSpain, held in Barcelona and at FarmaForum, held in Madrid.
October is the most outstanding month in terms of activity and representation of our partners both nationally and internationally. Women in Data Science 2023, Spanish Meeting on Oligonucleotide Therapeutics, 19th Annual OTS Meeting or CPHI 2023 have been a strategic place to present the progress of partners in the field of oligonucleotides.
Over the course of 2023, we have shared with the scientific community and the media a project backed by the expertise of our partners that makes us deeply proud.
We have certainly reached a significant milestone in our communication strategy this year, with the publication of 42 entries in the blog our website. In addition, we strengthened our presence on social channels, sharing 495 posts on Twitter and 493 on LinkedIn. On YouTube, we have enriched our content with a total of 26 long-format videos, mostly composed of interviews with our valued partners, and 16 short films, mainly focused on informative aspects.
A notable aspect of our communications exercise this year has been the high-profile series on drug development, the immersive “Getting to know more about…” carousels, designed to provide an in-depth introduction to our partners, and the engaging #DiscoveringOligonucleotides series.
Looking ahead to 2024, we are committed to squeeze every moment to consolidate Oligofastx’s presence as an internationally recognised project. We thank all those who, directly or indirectly, contribute to the support of this project.
We wish you all a happy and prosperous 2024!